Drug Trial Radar · NCT07028632
The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease
Last checked: Nov 20, 2026Latest source record: Jun 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Jun 30, 2025
Primary completion
Dec 2026
Study completion Dec 2030
Sponsor
- Lead sponsor
- iRegene Therapeutics Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of a single injection of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in patients with Parkinson's disease.
Conditions
- Parkinson Disease (PD)
Interventions
Human Dopaminergic Progenitor CellsBiological
Single injection of Human Dopaminergic Progenitor Cells into the putamen/striatum region of brain.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Motor FunctionTime frame: 24 weeks and 48 weeks post-transplant
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.